Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic Leukemia
Introduction: Acute promyelocytic leukemia treatment revolutionized by new tretaMNETS. Currently number of patinets who undergoe hematopoietic stem cell transplantation decrased so experience with this modality is limited. Here we report our experience with stem cell transplantation in acute promyel...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2011-03-01
|
| Series: | International Journal of Hematology-Oncology and Stem Cell Research |
| Subjects: | |
| Online Access: | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/265 |
| _version_ | 1797726536013447168 |
|---|---|
| author | Kamran Alimoghaddam Ardeshir Ghavamzadeh Mohamad Jahani Arash Jalali Hoda Jorjani Massoud Iravani Amir Ali Hamidieh Asadolah Mousavi Babak Bahar Maryam Behfar Roshanak Derakhshandeh Shahrbanoo Rostami |
| author_facet | Kamran Alimoghaddam Ardeshir Ghavamzadeh Mohamad Jahani Arash Jalali Hoda Jorjani Massoud Iravani Amir Ali Hamidieh Asadolah Mousavi Babak Bahar Maryam Behfar Roshanak Derakhshandeh Shahrbanoo Rostami |
| author_sort | Kamran Alimoghaddam |
| collection | DOAJ |
| description | Introduction: Acute promyelocytic leukemia treatment revolutionized by new tretaMNETS. Currently number of patinets who undergoe hematopoietic stem cell transplantation decrased so experience with this modality is limited. Here we report our experience with stem cell transplantation in acute promyelocytic leukemia patients. Design and setting: retrospective, single center
Methods: between year 2000 and 2011 we performed 20 HSCT in APL. Median age of patients was 25 year old. Patients received 3 autologous and 17 allogeneic HSCT from their HLA full match sibling donor. Different type of conditioning regimens applied for them. We used Cyclosporine and Methotraxtae as prophylaxis of GVHD after allogeneic HSCT.
Results: Hematopoietic stem cell engraftment observed in all cases. Acute GVHD was mild to moderate in all except one and was manageable.one patient dies due to aGVHD. Chronic GVHD was extensive in 2 cases and one mortality observed due to sever cGVHD. Mortality rate was 35% with a median follow up of 3.5 years. Five patinets died due to their primary disease relapse after HSCT. Three years DFS and OS were 63.1 and 77.2% respectively.
Conclusion: hematopoietic stem cell transplantation is an acceptable consolidation for APL. Choosing between autologous or allogeneic transplantation, need facilities such as reliable method for molecular remission detection before HSCT and also close and reliable follow up of patients with clinical and molecular parameters. |
| first_indexed | 2024-03-12T10:47:02Z |
| format | Article |
| id | doaj.art-dbb03cb446a2458692caa0f7b76e3237 |
| institution | Directory Open Access Journal |
| issn | 2008-2207 |
| language | English |
| last_indexed | 2024-03-12T10:47:02Z |
| publishDate | 2011-03-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | International Journal of Hematology-Oncology and Stem Cell Research |
| spelling | doaj.art-dbb03cb446a2458692caa0f7b76e32372023-09-02T07:30:03ZengTehran University of Medical SciencesInternational Journal of Hematology-Oncology and Stem Cell Research2008-22072011-03-0151Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic LeukemiaKamran Alimoghaddam0Ardeshir Ghavamzadeh1Mohamad Jahani2Arash Jalali3Hoda Jorjani4Massoud Iravani5Amir Ali Hamidieh6Asadolah Mousavi7Babak Bahar8Maryam Behfar9Roshanak Derakhshandeh10Shahrbanoo Rostami11Hematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranHematology Oncology and Stem Cell Transplantation Research Center of Tehran University of Medical Sciences, Tehran, IranIntroduction: Acute promyelocytic leukemia treatment revolutionized by new tretaMNETS. Currently number of patinets who undergoe hematopoietic stem cell transplantation decrased so experience with this modality is limited. Here we report our experience with stem cell transplantation in acute promyelocytic leukemia patients. Design and setting: retrospective, single center Methods: between year 2000 and 2011 we performed 20 HSCT in APL. Median age of patients was 25 year old. Patients received 3 autologous and 17 allogeneic HSCT from their HLA full match sibling donor. Different type of conditioning regimens applied for them. We used Cyclosporine and Methotraxtae as prophylaxis of GVHD after allogeneic HSCT. Results: Hematopoietic stem cell engraftment observed in all cases. Acute GVHD was mild to moderate in all except one and was manageable.one patient dies due to aGVHD. Chronic GVHD was extensive in 2 cases and one mortality observed due to sever cGVHD. Mortality rate was 35% with a median follow up of 3.5 years. Five patinets died due to their primary disease relapse after HSCT. Three years DFS and OS were 63.1 and 77.2% respectively. Conclusion: hematopoietic stem cell transplantation is an acceptable consolidation for APL. Choosing between autologous or allogeneic transplantation, need facilities such as reliable method for molecular remission detection before HSCT and also close and reliable follow up of patients with clinical and molecular parameters.https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/265Hematopoietic Stem Cell TransplantationAcute Promyelocytic LeukemiaAPLPML-RARa Positive APL |
| spellingShingle | Kamran Alimoghaddam Ardeshir Ghavamzadeh Mohamad Jahani Arash Jalali Hoda Jorjani Massoud Iravani Amir Ali Hamidieh Asadolah Mousavi Babak Bahar Maryam Behfar Roshanak Derakhshandeh Shahrbanoo Rostami Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic Leukemia International Journal of Hematology-Oncology and Stem Cell Research Hematopoietic Stem Cell Transplantation Acute Promyelocytic Leukemia APL PML-RARa Positive APL |
| title | Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic Leukemia |
| title_full | Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic Leukemia |
| title_fullStr | Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic Leukemia |
| title_full_unstemmed | Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic Leukemia |
| title_short | Hematopoietic Stem Cell Transplantation in PML-RARa Positive Acute Promyelocytic Leukemia |
| title_sort | hematopoietic stem cell transplantation in pml rara positive acute promyelocytic leukemia |
| topic | Hematopoietic Stem Cell Transplantation Acute Promyelocytic Leukemia APL PML-RARa Positive APL |
| url | https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/265 |
| work_keys_str_mv | AT kamranalimoghaddam hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT ardeshirghavamzadeh hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT mohamadjahani hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT arashjalali hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT hodajorjani hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT massoudiravani hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT amiralihamidieh hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT asadolahmousavi hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT babakbahar hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT maryambehfar hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT roshanakderakhshandeh hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia AT shahrbanoorostami hematopoieticstemcelltransplantationinpmlrarapositiveacutepromyelocyticleukemia |